BackBicara Therapeutics Common Stock Overview

Bicara Therapeutics Common Stock Receivables

Bicara Therapeutics Common Stock's receivables is $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer trimmed avg / median

Loading

Bicara Therapeutics Common Stock Receivables History

Loading

Bicara Therapeutics Common Stock vs. peers: Receivables Comparison

Loading

Bicara Therapeutics Common Stock Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Bicara Therapeutics Common Stock (BCAX) FAQ

As of the most recent data (June 2026), BCAX shows a receivables of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BCAX's receivables is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Bicara Therapeutics Common Stock is outperforming or lagging.

Tracking BCAX's receivables over time shows whether Bicara Therapeutics Common Stock is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Bicara Therapeutics Common Stock's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $0) with ownership activity and broader fundamentals.

Bicara Therapeutics Common Stock's receivables is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.